Novo Nordisk partners with AI startup Cellular Intelligence on Parkinson's cell therapy

Novo Nordisk A/S announced a partnership with Cellular Intelligence, an artificial‑intelligence company backed by Mark Zuckerberg, to advance an experimental Parkinson’s disease cell‑therapy program. The deal will see Cellular Intelligence take responsibility for developing the therapy, aiming to accelerate its progress through AI‑driven approaches.

Cellular Intelligence described the program as “truly innovative,” highlighting the convergence of academic discovery with the “uncompromising quality of a global pharmaceutical leader.” The collaboration reflects growing interest in using AI to streamline drug development for neurodegenerative diseases.